Join
Live feed
·
PRReleasevia Quantisnow
4D pharma plc logo

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

ByQuantisnow·Wall Street's wire, on your screen.
LBPS· 4D pharma plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LBPS (4D pharma plc) and more on Quantisnow.